A Phase 1, Open-Label, Multicenter, Multi-Dose Escalation Study of CM-24 (MK-6018) as Monotherapy and In Combination With Pembrolizumab (MK-3475) in Subjects With Selected Advanced or Recurrent Malignancies
Phase of Trial: Phase I
Latest Information Update: 20 Mar 2017
At a glance
- Drugs CM 24 (Primary)
- Indications Bladder cancer; Colorectal cancer; Gastric cancer; Malignant melanoma; Non-small cell lung cancer; Ovarian cancer
- Focus Adverse reactions; First in man
- Sponsors cCAM Biotherapeutics; Merck Sharp & Dohme
- 15 Mar 2017 Status changed from active, no longer recruiting to discontinued.
- 23 Feb 2017 Planned End Date changed from 1 Feb 2017 to 1 Jun 2017.
- 23 Feb 2017 Planned primary completion date changed from 1 Feb 2017 to 1 Jun 2017.